- Details
- In this conversation with Alicia Morgans, MD, MPH, Siamak (Sia) Daneshmand discusses long-term follow-up of testicular cancer patients, a topic of interest to many navigating testicular cancer survivorship. Dr. Daneshmand provided an oral abstract discussion during the 2021 ASCO annual meeting highlighting two abstracts Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in...
|
- Details
- Bone strengthening agents such as bisphosphonates or the RANKL-targeting antibody denosumab reduced the bone loss associated with androgen deprivation therapy (ADT) and prevent skeletal-related events in castration resistant prostate cancer (CRPC). The use of these agents is recommended in CRPC by many guidelines. The randomized phase III EORTC-1333-GUCG also known as the PEACE-III trial, compares...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD discussed the updated results of the KEYNOTE-052 trial up to 5 years of follow-up. KEYNOTE-052 was a multicentre, single-arm, phase 2 study that launched several years ago tested pembrolizumab in the first-line setting in cisplatin-ineligible patients with advanced urothelial cancer. The goal of KEYNOTE-052 was to evaluate the role...
|
- Details
- Arjun Balar, MD, joins Alicia Morgans, MD, MPH in a discussion on INDUCE-1, the a first-in-human trial evaluating feladilimab as monotherapy and in combination with pembrolizumab. In an oral abstract session at the 2021 ASCO annual meeting, Dr. Arjun Balar presented results of INDUCE-1 assessing preliminary efficacy, safety, and biomarker data of feladilimab ± pembrolizumab in urothelial carcinoma...
|
- Details
- In a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi presented the first results of the PEACE-1 trial. PEACE-1 is a phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer. Adding abiraterone to ADT + docetaxel significantly impro...
|
- Details
- Following androgen deprivation therapy (ADT) which was introduced decades prior, the TAX-327 trial of docetaxel for patients with metastatic castration-resistant prostate cancer was the first to demonstrate a survival advantage for systemic treatment in prostate cancer. Since then, docetaxel has proven survival benefit for men with metastatic castration-sensitive disease. However, the benefit of d...
|
- Details
- Oliver Sartor, MD, the CO-PI on the VISION Trial joins Alicia Morgans, MD, MPH in a conversation on the practice-changing VISION Trial results presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. 177Lu-PSMA-617 is a targeted radioligand therapy that delivers ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment. The VISION study was an int...
|
- Details
- Rana McKay, MD joins Alicia Morgans, MD, MPH in a discussion on the potential paradigm shift in the treatment landscape for high-risk kidney cancer with the findings from the KEYNOTE-564 trial. Dr. McKay was the discussant in the plenary session at the 2021 ASCO meeting following the presentation of the results by Toni Choueiri, MD. The phase 3 KEYNOTE-564 trial is a randomized, double-blind, plac...
|
- Details
- Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or death (median rPFS benefit of 5 months) compared to best standard of care alone. Mary-Ellen Taplin, Professor of Medicine and a GU Medical Oncologist at Dana-Farber Cancer Institute, joins Alicia Morga...
|
- Details
- In a plenary presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Michael Morris, MD, presented awaited results of the Phase III VISION trial. The study is evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard o...
|
